Table 3.
Association with CD4/CD8 ratio at time of first vaccination. OR and AOR, by fitting a logistic regression model, of the probability of failing to achieve a robust/above-average anti-S/RBD response post-vaccination, with VE90% (Panel A) and OCOnAbs (Panel B) endpoints.
| Panel A (VE 90% Endpoint) |
Unadjusted OR (95% CI) | p-Value | Adjusted * OR (95% CI) | p-Value | & Type III p-Value |
|---|---|---|---|---|---|
| CD4/CD8 ratio at T1 | Failed to achieve VE90% after primary cycle (T3) | ||||
| HR | 1 | 1 | 0.311 | ||
| IR | 1.13 (0.85, 1.50) | 0.393 | 0.76 (0.42, 1.36) | 0.356 | |
| LR | 1.74 (1.31, 2.32) | <0.001 | 1.17 (0.63, 2.17) | 0.612 | |
| Per 1 SD lower (log 2 scale) | 1.28 (1.14, 1.44) | <0.001 | 1.15 (0.90, 1.49) | 0.267 | |
| CD4/CD8 ratio at T1 | Failed to achieve VE90% after first booster dose (T5) | ||||
| HR | 1 | 1 | 0.474 | ||
| IR | 1.12 (0.67, 1.89) | 0.659 | 0.58 (0.23, 1.46) | 0.247 | |
| LR | 1.50 (0.92, 2.45) | 0.106 | 0.82 (0.33, 2.05) | 0.677 | |
| Per 1 SD lower (log 2 scale) | 1.31 (1.09, 1.57) | 0.004 | 0.98 (0.68, 1.41) | 0.921 | |
|
PANEL B
(OCOnAbs Endpoint) |
Unadjusted OR (95% CI) | p -Value | Adjusted OR (95% CI) | p -Value | & Type III p-Value |
| CD4/CD8 ratio at T1 | Failed to achieve OCOnAbs after primary cycle (T3) | ||||
| HR | 1 | 1 | 0.912 | ||
| IR | 0.95 (0.71, 1.29) | 0.751 | 0.91 (0.50, 1.64) | 0.745 | |
| LR | 1.43 (1.04, 1.95) | 0.026 | 1.02 (0.54, 1.93) | 0.949 | |
| Per 1 SD lower (log 2 scale) | 1.18 (1.05, 1.34) | 0.007 | 0.99 (0.76, 1.30) | 0.964 | |
| CD4/CD8 ratio T1 | Failed to achieve OCOnAbs after first booster dose (T5) | ||||
| HR | 1 | 1 | 0.396 | ||
| IR | 0.97 (0.59, 1.60) | 0.900 | 0.65 (0.27, 1.56) | 0.332 | |
| LR | 1.35 (0.84, 2.16) | 0.216 | 1.06 (0.44, 2.55) | 0.898 | |
| Per 1 SD lower (log 2 scale) | 1.27 (1.06, 1.52) | 0.009 | 1.09 (0.77, 1.54) | 0.635 | |
* Adjusted for age, VL ≤ 50 cps/mL at 1st vaccination, no. of comorbidities and nadir CD4 count; & from the adjusted model. Abbreviations: HR, high CD4/CD8 ratio (>1); IR, intermediate CD4/CD8 ratio (0.60–0.99); LR, low CD4/CD8 ratio (0–0.59); OR, odds ratio.